Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Sanofi : bolsters its position on multiple sclerosis with a $765M BTK licensing deal

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 05:12pm CEST

Sanofi is snapping up an early-stage program from San Franciscos Principia Biopharma, shoring up the pharma giants position in multiple sclerosis.

Sanofi will write a check for $40 million upfront, with future milestone payments that could total $765 million. In return, Sanofi gets a worldwide license to develop and sell PRN2246. The asset, which just entered Phase I clinical trials, is a BTK inhibitor designed to access the brain and spinal column by crossing the blood-brain barrier. Once there, its meant to impact immune cell and brain cell signaling. The companies hope this may treat MS and other central nervous system diseases.

The asset makes sense for Sanofi, as the drug maker already has two successful MS drugs on the shelves: Aubagio and Lemtrada. The two products make up a significant part of Sanofis overall revenue.

Sanofis neuroscience research head Rita Balice-Gordon said the investment highlights Sanofis focus on MS and neurological disease.

Complementing our own internal R&D expertise, external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases, Balice-Gordon said.

Principias CEO Martin Babler said partnering with a pharma giant with MS experience allows the startup to make better use of its resources.

The agreement allows Principia to maximize the BTK opportunity in neurology with a strong partner for PRN2246 while focusing internal resources on our lead BTK inhibitor in another therapeutic area, Babler said.

The companys lead program, PRN1008, is in Phase II trials in patients with pemphigus, an orphan autoimmune disease.

The deal between Sanofi and Principia is a tad open-ended. Principia has the option to co-fund Phase III development, should the asset progress that far. If they choose that option, they can get increased royalties on global sales or a profit and loss sharing agreement in the US.

The transaction is expected to close in the fourth quarter.

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
12:34pNovo Nordisk picks AstraZeneca executive to head biopharma business
10/13SANOFI : Philippines' 'highly politicized' response to Dengvaxia mess erodes pub..
10/10HIKMA PHARMACEUTICALS : Ventures participates in a $19 million round for Click T..
10/10SANOFI : REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Pha..
10/08SANOFI : Disclosure of trading in own shares
10/08SANOFI : Disclosure of trading in own shares
10/03REGENERON PHARMACEUTICALS : Fda approves libtayo as first and only treatment for..
10/03SANOFI : taps startup Researchably to use AI to sift through new research
10/03SANOFI : FDA Approves Sanofi and Regeneron`s Libtayo
10/02SANOFI : Buscopan in Philippines has no adverse effects Sanofi
More news
News from SeekingAlpha
10/13STOCKS TO WATCH : Was That A Speed Bump? 
10/12Merck bails on Lantus biosimilar 
10/10Novartis' crizanlizumab showed effect on vaso-occlusive crises in mid-stage s.. 
10/09Altimmune Declines Too Much 
10/09Premarket analyst action - healthcare 
At a crossroads
Financials (€)
Sales 2018 35 005 M
EBIT 2018 8 399 M
Net income 2018 4 995 M
Debt 2018 16 265 M
Yield 2018 4,08%
P/E ratio 2018 17,85
P/E ratio 2019 16,63
EV / Sales 2018 3,10x
EV / Sales 2019 3,00x
Capitalization 92 355 M
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 79,9 €
Spread / Average Target 8,3%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI2.69%106 748
JOHNSON & JOHNSON-4.19%359 060
PFIZER20.87%250 957
NOVARTIS-0.49%211 413
ROCHE HOLDING LTD.-4.44%204 875
MERCK AND COMPANY24.06%181 832